---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002690"
form_type: "8-K"
ticker: "STRO"
cik: "0001382101"
company_name: "SUTRO BIOPHARMA, INC."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:07:32.610123+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sutro Biopharma reports ~$333M cash, luvelta data in ovarian cancer, AML, NSCLC trials planned

## Summary
- Preliminary cash, equivalents, marketable securities ~$333M as of Dec 31, 2023; 0.7M shares of Vaxcyte stock valued ~$42M, funding into 2H2025.
- Updated luvelta data in ovarian cancer: improved clinical outcomes and tolerability vs historical chemo; prophylactic G-CSF reduced neutropenia/dose delays.
- Luvelta + bevacizumab showed clinical activity regardless of FolRα expression; preclinical NSCLC data showed single-dose activity and benefit with PD-1 blockade.
- REFRαME-O1 registration trial in platinum-resistant ovarian cancer enrolling, Part 1 completion expected 1H2024, ~140 sites by end of 2024.
- REFRαME-P1 trial initiation in pediatric CBF/GLIS AML planned 1H2024; IND submission in NSCLC planned 1H2024; endometrial cancer development ongoing.

## SEC filing metadata
- accession: 0000950170-24-002690
- form_type: 8-K
- ticker: STRO
- cik: 0001382101
- company_name: SUTRO BIOPHARMA, INC.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/0000950170-24-002690-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1382101/000095017024002690/stro-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002690
- JSON: https://secwatch.observer/filing/0000950170-24-002690.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002690.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.